JDRF is committed to facilitating the translation of therapies to improve outcomes in those with Type 1 Diabetes (T1D) and diabetic nephropathy (DN). Clinical trial design in this area is difficult due to the lack of validated biomarkers to predict progression to more severe disease and/or to predict treatment response ahead of endpoints currently acceptable to regulatory authorities. JDRF wishes to address this gap by utilizing well characterized T1D cohorts to discover and validate such biomarkers. The aim of this request is to catalyze collaborative research between talented research groups with critical clinical and data resources as well as those with appropriate analytic methods in order to accelerate progress in DN biomarker validation towards clinical utility.
E/LOI Deadline 7/14/2014 – Application Deadline 10/2014